PortfoliosLab logo
Bicycle Therapeutics plc (BCYC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0887861088

CUSIP

088786108

IPO Date

May 23, 2019

Highlights

Market Cap

$595.58M

EPS (TTM)

-$3.16

Total Revenue (TTM)

$25.73M

Gross Profit (TTM)

$20.17M

EBITDA (TTM)

-$219.83M

Year Range

$6.10 - $28.67

Target Price

$26.27

Short %

8.63%

Short Ratio

7.25

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Bicycle Therapeutics plc (BCYC) returned -38.57% year-to-date (YTD) and -62.43% over the past 12 months.


BCYC

YTD

-38.57%

1M

28.36%

6M

-64.64%

1Y

-62.43%

5Y*

-10.17%

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of BCYC, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-4.36%-18.07%-22.61%0.82%0.47%-38.57%
2024-3.48%43.78%-0.76%-5.82%-5.37%-8.79%20.11%-11.56%5.26%3.60%-12.99%-31.37%-22.57%
2023-6.69%-17.70%-6.42%-7.10%21.36%6.42%-3.61%-11.63%-7.59%-25.09%-4.32%25.56%-38.92%
2022-19.78%-2.72%-7.62%-46.49%-31.90%4.94%40.41%12.27%-12.06%6.41%17.01%2.21%-51.37%
202149.36%-5.74%18.20%3.78%-4.84%2.92%4.08%12.97%16.50%23.59%4.57%13.25%239.11%
202015.38%18.84%5.57%-6.23%39.61%-11.92%0.38%13.73%6.01%-2.83%15.40%-15.96%90.35%
2019-2.58%-13.94%-17.88%-11.15%55.18%-15.19%-9.32%7.65%-21.42%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BCYC is 6, meaning it’s performing worse than 94% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BCYC is 66
Overall Rank
The Sharpe Ratio Rank of BCYC is 77
Sharpe Ratio Rank
The Sortino Ratio Rank of BCYC is 66
Sortino Ratio Rank
The Omega Ratio Rank of BCYC is 66
Omega Ratio Rank
The Calmar Ratio Rank of BCYC is 88
Calmar Ratio Rank
The Martin Ratio Rank of BCYC is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bicycle Therapeutics plc (BCYC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Bicycle Therapeutics plc Sharpe ratios as of May 13, 2025 (values are recalculated daily):

  • 1-Year: -0.87
  • 5-Year: -0.15
  • All Time: -0.07

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Bicycle Therapeutics plc compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Bicycle Therapeutics plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Bicycle Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bicycle Therapeutics plc was 89.56%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Bicycle Therapeutics plc drawdown is 85.93%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-89.56%Nov 16, 2021851Apr 8, 2025
-53.96%Jun 20, 201949Aug 28, 2019117Feb 14, 2020166
-41.61%Mar 11, 20209Mar 23, 202046May 28, 202055
-25.95%Feb 8, 202118Mar 4, 202120Apr 1, 202138
-20.84%Jul 26, 202119Aug 19, 20217Aug 30, 202126

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bicycle Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Bicycle Therapeutics plc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -8.8%.


-1.50-1.00-0.500.0020212022202320242025
-0.88
-0.81
Actual
Estimate

Valuation

The Valuation section provides an overview of how Bicycle Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BCYC relative to other companies in the Biotechnology industry. Currently, BCYC has a P/S ratio of 23.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BCYC in comparison with other companies in the Biotechnology industry. Currently, BCYC has a P/B value of 0.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items